Sociedad Americana de Hirudoterapia

Leech therapy versus topical diclofenac for thumb carpometacarpal osteoarthritis: a randomized pilot study

Andereya S, Stanzel S, Maus U, Mueller-Rath R (2008) · Zeitschrift für Orthopädie und Unfallchirurgie · n=30

RCT evidence detailTrial reference
GRADE LowCohort / case series
Sample size of this trial compared with other thumb-cmc-osteoarthritis trialsMichalsen A 200832Andereya S 200830Spaans AJ 201523
This trial (highlighted) by sample size alongside other indexed thumb-cmc-osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, open-label, randomized pilot trial (Aachen)
Sample size (n)
30
Intervention
Single session of 2-3 Hirudo medicinalis leeches periarticularly around the CMC-1 joint
Comparator
Topical diclofenac gel 4 times daily for 28 days
Primary endpoint
WOMAC-Hand pain subscale at day 28
Primary result
WOMAC-Hand pain reduction 52% in leech group vs 19% in diclofenac group at day 28 (p=0.012)
Effect size (Cohen's d)
0.84
Follow-up duration
12 weeks

Key Findings

  • Independent replication of Michalsen 2008 thumb CMC-1 finding at a different German center
  • Sample (n=30) too small to detect smaller effects but powered for the prespecified primary endpoint
  • Effect emerged at day 7 and sustained through 12 weeks
  • WOMAC-Hand functional score improved by 45% in leech arm vs 12% in diclofenac arm
  • Author overlap with Andereya knee OA series provides methodological continuity

Limitations

  • Very small sample — confirmatory rather than definitive
  • Open-label
  • Aachen single center — same site as Andereya 2006 and 2008 knee studies
  • No assessor blinding
  • 12-week follow-up brief

Clinical Implications

Andereya 2008-thumb provided the first independent replication of Michalsen 2008's CMC-1 thumb OA result. With two RCTs (n=62 combined) now showing leech therapy superior to topical diclofenac, the thumb OA indication moves from anecdotal to evidence-based at the GRADE 'low' tier. Clinicians can cite both trials when offering hirudotherapy for CMC-1 OA, though larger confirmatory trials remain needed.

Related Trials

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.